Recent developments on therapeutic and diagnostic approaches for COVID-19
J Majumder, T Minko - The AAPS journal, 2021 - Springer
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health …
Coronavirus disease 2019 (COVID-19): current status and future perspectives
H Li, SM Liu, XH Yu, SL Tang, CK Tang - International journal of …, 2020 - Elsevier
ABSTRACT Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei
Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is …
Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is …
The impact of pre-existing comorbidities and therapeutic interventions on COVID-19
LA Callender, M Curran, SM Bates… - Frontiers in …, 2020 - frontiersin.org
Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals
with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of …
with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of …
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly
spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a …
spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a …
Drug repurposing strategy (DRS): Emerging approach to identify potential therapeutics for treatment of novel coronavirus infection
BM Sahoo, BVV Ravi Kumar, J Sruti… - Frontiers in Molecular …, 2021 - frontiersin.org
Drug repurposing is also termed as drug repositioning or therapeutic switching. This method
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …
is applied to identify the novel therapeutic agents from the existing FDA approved clinically …
Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19
W Cui, K Yang, H Yang - Frontiers in molecular biosciences, 2020 - frontiersin.org
The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2)
rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19) …
rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19) …
Progress in developing inhibitors of SARS-CoV-2 3C-like protease
Q Li, CB Kang - Microorganisms, 2020 - mdpi.com
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a …
coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a …
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
Background New antiretroviral therapy (ART) regimens for HIV could improve clinical
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …
[HTML][HTML] Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
When To Start Consortium - The Lancet, 2009 - Elsevier
BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
Lopinavir/ritonavir: a review of its use in the management of HIV infection
RS Cvetkovic, KL Goa - Drugs, 2003 - Springer
Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with
low-dose ritonavir significantly improves the pharmacokinetic properties and hence the …
low-dose ritonavir significantly improves the pharmacokinetic properties and hence the …